# EDGAR Filing Document

**Accession Number:** 0001874252
**File Stem:** 0001213900-26-014378
**Filing Date:** 2026-2
**Character Count:** 25453
**Document Hash:** 0a1ab039616a0f941affc7c1cffe12cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-014378.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001213900-26-014378

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251229

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAINZ BIOMED N.V.
- **CENTRAL INDEX KEY:** 0001874252
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41010
- **FILM NUMBER:** 26617006

**BUSINESS ADDRESS:**
- **STREET 1:** ROBERT KOCH STRASSE 50
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55129
- **BUSINESS PHONE:** 49 6131 5542860

**MAIL ADDRESS:**
- **STREET 1:** ROBERT KOCH STRASSE 50
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mainz Biomed B.V.
- **DATE OF NAME CHANGE:** 20210721

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): December 29, 2025**

---

| |
|:---|
| **MAINZ BIOMED N.V.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **The Netherlands** | **001-41010** | **N/A** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **Robert Koch Strasse 50**<br> **Mainz, Germany** | **55129** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(407) 344 4004**

**<u>N/A</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary Shares, €0.01 par value | MYNZ | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

As previously disclosed in a current report on Form 6-K dated October 3, 2025, on October 1, 2025, Mainz Biomed N.V. (the "Company"), a Dutch public limited liability entered into an equity distribution agreement (the "Sales Agreement") with Maxim Group LLC ("Maxim" or the "Sales Agent"), a New York-based broker-dealer. The Sales Agreement provides a framework under which the Company may sell, from time to time, ordinary shares, nominal value €0.01 per share (the "Ordinary Shares"), representing an aggregate maximum offering amount of up to $10,000,000 (the "ATM").

A copy of the Sales Agreement is filed as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference.

With respect to the Company's ATM, on December 29, 2025, the Company filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), dated as of December 29, 2025, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the "Securities Act"), which supplements the Company's effective shelf registration statement on Form F-3 (File No. 333-269091) originally filed on December 30, 2022 and declared effective on January 6, 2023 (the "Base Prospectus"). The Prospectus Supplement describes the terms of the ATM with Maxim regarding the sale of Ordinary Shares under the Sales Agreement. Pursuant to the Prospectus Supplement and the accompanying Base Prospectus, the Company may offer and sell Ordinary Shares through the Sales Agent having an aggregate maximum offering price of $2,152,823.

From January 5, 2026 through January 23, 2026, the Company sold an aggregate of 1,735,194 Ordinary Shares under the Prospectus Supplement at prevailing market prices on the Nasdaq Capital Market through the Sales Agent. The Company received aggregate gross proceeds of $2,152,822.40 before deducting commissions and expenses payable to Maxim.

As of the date of this current report on Form 8-K, the Prospectus Supplement has been fully utilized. The remaining capacity under the overall ATM remains available for future sales, subject to market conditions and other factors.

This Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Offered Shares or any other securities, nor shall there be any offer, solicitation, or sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

**Item 9.01 Financial Statements and Exhibits.**

<u>Exhibit Index</u>

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 5.1 | [Opinion of CMS Derks Star Busmann N.V. regarding the validity of the securities being registered](ea027509801ex5-1_mainz.htm) |
| 10.1 | [Sales Agreement, dated October 3, 2025, by and among Mainz Biomed N.V. and Maxim Group LLC (incorporated by reference to Exhibit 10.1 to the current report on Form 6-K by the Registrant on October 3, 2025).](http://www.sec.gov/Archives/edgar/data/1874252/000121390025096195/ea026027901ex10-1_mainz.htm) |
| 23.1 | [Consent of CMS Derks Star Busmann N.V. (included in Exhibit 5.1)](ea027509801ex5-1_mainz.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

The information contained in this Report on Form 6-K is hereby incorporated by reference into our Registration Statement on Form F-3 (File No. 333-269091) and into the Base Prospectus and any prospectus supplement outstanding under the foregoing registration statement.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 10, 2026 | By: | */s/ William J. Caragol* |
|  |  | Chief Financial Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | | |
|:---|:---|:---|
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | **CMS Derks Star Busmann N.V.**<br> Atrium \| Parnassusweg 737<br> NL-1077 DG Amsterdam<br> P.O. Box 94700<br> NL-1090 GS Amsterdam | **CMS Derks Star Busmann N.V.**<br> Atrium \| Parnassusweg 737<br> NL-1077 DG Amsterdam<br> P.O. Box 94700<br> NL-1090 GS Amsterdam |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | Bank account (Stichting Derdengelden) | Bank account (Stichting Derdengelden) |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | Iban: NL31 RABO 0103 3545 49 | Iban: NL31 RABO 0103 3545 49 |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | Swift/bic: RABONL2U | Swift/bic: RABONL2U |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY |  |  |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | **T** | +31 20 301 63 01 |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | **F** | +31 20 301 63 05 |
| <br>Mainz Biomed N.V.<br> Robert Koch Strasse 50<br> 55129 Mainz<br> GERMANY | **I** | cms.law |

---

---

| | | |
|:---|:---|:---|
| **Subject:** | **Mainz Biomed N.V. / Legal opinion** | 10 February 2026 |

---

Dear Madam/Sir,

We have acted as Dutch legal counsel to Mainz Biomed N.V. of Amsterdam, the Netherlands (the "**Company**"), in respect of certain matters of Dutch law in connection with an offering of ordinary shares in the capital of the Company with a nominal value of EUR 0.01 up to USD 2,152,823 (the "**Registration Shares**"). The Registration Shares are being offered pursuant to a prospectus supplement (the "**Prospectus Supplement**") filed by the Company on 29 December 2025.

For the purpose of this legal opinion, we have examined and relied solely upon the following documents:

(a) an electronically received copy of an extract relative to the Company, dated 10 February 2026 (the "**Extract** ")
from the trade register (*handelsregister*) of the Dutch Chamber of Commerce (*Kamer van Koophandel*) (the "**Trade Register** ");

(b) an official copy (*afschrift*) of the notarial deed of incorporation (*akte van oprichting*)
of the Company, dated 8 March 2021 (the "**Deed of Incorporation** "), containing the articles of association of the Company
before the execution of the Deed of Conversion;

---

| |
|:---|
| All services are rendered under an agreement of instruction with CMS Derks Star Busmann N.V., with registered office in Amsterdam, the Netherlands. This agreement is subject to the General Conditions of CMS Derks Star Busmann N.V., which have been filed with the registrar of the District Court Amsterdam, the Netherlands, under no. 84/2020 and which contain a limitation of liability. These terms have been published on the website cms.law and will be provided upon request. CMS Derks Star Busmann N.V. is a company with limited liability under the laws of the Netherlands and is registered in the Netherlands with the trade register under no. 30201194 and in Belgium with the RPR Brussels under no. 0877.478.727. The VAT number of CMS Derks Star Busmann N.V. for the Netherlands is NL8140.16.479.B01 and for Belgium BE 0877.478.727. |
| CMS Derks Star Busmann is a member of CMS, the organisation of European law firms. In certain circumstances, CMS is used as a brand or business name of, or to refer to, some or all of the member firms or their offices. Further information can be found at www.cms.law. |
| CMS offices and associated offices: Aberdeen, Algiers, Amsterdam, Antwerp, Barcelona, Beijing, Belgrade, Berlin, Bogotá, Bratislava, Bristol, Brussels, Bucharest, Budapest, Casablanca, Cologne, Dubai, Duesseldorf, Edinburgh, Frankfurt, Funchal, Geneva, Glasgow, Hamburg, Hong Kong, Istanbul, Johannesburg, Kyiv, Leipzig, Lima, Lisbon, Ljubljana, London, Luanda, Luxembourg, Lyon, Madrid, Manchester, Mexico City, Milan, Mombasa, Monaco, Moscow, Munich, Muscat, Nairobi, Paris, Podgorica, Poznan, Prague, Reading, Rio de Janeiro, Riyadh, Rome, Santiago de Chile, Sarajevo, Seville, Shanghai, Sheffield, Singapore, Skopje, Sofia, Strasbourg, Stuttgart, Tirana, Utrecht, Vienna, Warsaw, Zagreb and Zurich. |

---

![A close-up of a logo AI-generated content may be incorrect.](ex5-1_001.jpg)

(c) an official copy of a notarial deed of conversion dated 9 November 2021 (the "**Deed of Conversion**") ;

(d) an official copy of the notarial deed of amendment of the articles of association of the Company, dated
13 November 2025 (the "**Deed of Amendment** "), containing the articles of association of the Company as of such date (the "**Articles of Association** ");

(e) a written resolution of the board (*bestuur*) of the Company, dated 9 February 2026 (the "**Board Resolution** ");

(f) a written resolution of the general meeting (*algemene vergadering*) of the Company, dated 1 November
2021 (the "**Shareholder Resolution** "); and

(g) an electronically received copy of the Prospectus Supplement.

We do not express any opinion in respect of the Prospectus Supplement.

In connection with such examination and for the purpose of the legal opinion expressed herein, we have assumed:

(i) that at the time of the issuance of the Registration Shares, the Company's authorized capital will
be sufficient to allow for their issuance;

(ii) that the Registration Shares will be offered, subscribed for, issued and accepted by the investors in
accordance with all applicable laws (including for the avoidance of doubt, Dutch law);

(iii) that the Registration Shares will be validly paid up at the time of the issuances;

(iv) that the Registration Shares will be issued in the form and manner prescribed by the articles of association
at the time of the issuances;

(v) that the Company will duly sign a deed of issue to implement each issuance of Registration Shares;

(vi) that each signature on each document is the original or electronic (as relevant) signature of the relevant
stated person;

(vii) the genuineness of all signatures on all original documents of the persons purported to have signed the
same;

(viii) the conformity to their originals of all documents submitted or transmitted to us in the form of photocopies,
electronically or otherwise, and the authenticity and completeness of such originals;

(ix) that the Shareholder Resolution and the Board Resolution have been validly signed and that the resolutions
reflected therein will be in full force and effect at the time of the issuance of the Registration Shares and that none of these resolutions
will be withdrawn or restated and that no resolutions have been or will be adopted to amend the contents of these resolutions;

(x) that the Deed of Incorporation, the Deed of Conversion and the Deed of Amendment are valid notarial deeds
(*notariële aktes*), that the content thereof is correct and complete, it being hereby confirmed that on the face of the Deed
of Incorporation, the Deed of Conversion and the Deed of Amendment it does not appear that these deeds are not valid notarial deeds;

Page<sub>2</sub>

![A close-up of a logo AI-generated content may be incorrect.](ex5-1_001.jpg)

(xi) that the Articles of Association are in full force and effect at the date hereof, it being hereby confirmed
that on the face of the Articles of Association and the Extract it does not appear that the Articles of Association are not in full force
and effect as at the date hereof;

(xii) that any and all authorisations and consents of, or other filings with or notifications to, any public
authority or other relevant body or person in or of any jurisdiction which may be required (other than under Dutch law) in respect of
the issuance of the Registration Shares have been or will be duly obtained or made, as the case may be;

(xiii) that no petition has been presented to, nor an order made by, a court for the bankruptcy (*faillissement*)
of the Company and that no resolution has been adopted concerning a statutory merger (*juridische fusie*) or division (*splitsing*)
involving the Company as disappearing entity, or a voluntary liquidation (*ontbinding*) of the Company;

(xiv) that the information contained in the Extract truly and correctly reflects the position of the Company
as mentioned therein;

(xv) that, at the time of the issuances of the Registration Shares, the Company, and the investors are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) not included on the consolidated list of persons, groups and entities subject to EU financial sanctions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) not subject to the restrictive measures deriving from Council Regulation (EU) 2022/262 and Council Decision
(CFSP) 2022/264, issued by the Council of the European Union on 23 February 2022, in view of Russia's actions destabilising the
situation in Ukraine;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) not subject to the restrictive measures deriving from Council Regulation (EU) 2022/334 and Council Decision
(CFSP) 2022/335, issued by the Council of the European Union on 28 February 2022, in view of Russia's actions destabilising the
situation in Ukraine;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) not subject to the restrictive measures deriving from Council Regulation (EU) 2022/428 and Council Decision
(CFSP) 2022/430, issued by the Council of the European Union on 15 March 2022, in view of Russia's actions destabilising the situation
in Ukraine; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) not subject to any other restrictive measures issued by the Council of the European Union, in view of
Russia's actions destabilising the situation in Ukraine;

(xvi) that, at the date hereof, the directors of the Company are not subject to a director's disqualification
(*civielrechtelijk bestuursverbod*) under Dutch law, which assumption is supported by the confirmation of the directors in the Board
Resolution; and

(xvii) that the Company has not been dissolved (*ontbonden*), merged (*gefuseerd*) involving the Company
as disappearing entity, demerged (*gesplitst*), converted (*omgezet*), granted a suspension of payments (*surséance verleend*), subjected to emergency regulations (*noodregeling*) as provided for in the Financial Supervision Act (*Wet op het Financieel Toezicht*), declared bankrupt (*failliet verklaard*), subjected to any other insolvency proceedings listed in Annex
A of Regulation (EU) 2015/848 of the European Parliament and of the Council of 20 May 2015 on insolvency proceedings (recast), as amended
by Regulation (EU) 2021/2260 of the European Parliament and of the Council of 15 December 2021 amending Regulation (EU) 2015/848 on insolvency
proceedings to replace its Annexes A and B, listed on the list referred to in article 2 (3) of Council Regulation (EC) No 2580/2001 of
27 December 2001, listed in Annex I to Council Regulation (EC) No 881/2002 of 27 May 2002 or listed and marked with an asterisk in the
Annex to Council Common Position 2001/931 of 27 December 2001 relating to measures to combat terrorism, as amended from time to time,
and no trustee (*curator*), administrator (*bewindvoerder*) or similar officer has been appointed in respect of the Company
or any of its respective assets.

Page<sub>3</sub>

![A close-up of a logo AI-generated content may be incorrect.](ex5-1_001.jpg)

We express no opinion as to any law other than the laws of the Netherlands in force at the date hereof as applied and interpreted according to present duly published case law of the Dutch courts. No opinion is rendered with respect to any matters of fact, anti-trust law, market abuse, equal treatment of shareholders, financial assistance, tax law or the laws of the European Communities, to the extent not or not fully implemented in the laws of the Netherlands.

In this legal opinion, Dutch legal concepts are expressed in English terms and not in their original Dutch terms. Where indicated in italics, Dutch equivalents of these English terms have been given for the purpose of clarification. The Dutch concepts may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions. Terms and expressions of law and of legal concepts as used in this legal opinion have the meaning attributed to them under the laws of the Netherlands and this legal opinion should be read and understood accordingly.

This legal opinion is strictly limited to the matters stated herein and may not be read as extending by implication to any matter not specifically referred to. Nothing in this legal opinion should be taken as expressing an opinion in respect of the factual accuracy of any representations or warranties, or other information, contained in any document, referred to herein or examined in connection with this legal opinion, except as expressly stated otherwise. For the purpose hereof, we have assumed such accuracy.

Based upon the foregoing (including, without limitation, the documents and the assumptions set out above) and subject to the qualifications set out below and any facts, circumstances, events or documents not disclosed to us in the course of our examination referred to above, we are, at the date hereof, of the opinion that:

When issued, the Registration Shares will have been validly issued, fully paid and will be non-assessable.

The opinion expressed above is subject to the following qualifications:

(A) The opinion expressed above may be affected or limited by any applicable bankruptcy, insolvency, fraudulent
conveyance *(actio pauliana*), reorganization, suspension of payment and other or similar laws now or hereafter in effect, relating
to or affecting the enforcement or protection of creditors' rights.

(B) A power of attorney (*volmacht*) or mandate (*lastgeving*) granted or issued by the Company
will terminate by force of law and without any notice being required upon bankruptcy of the Company and will become ineffective upon a
suspension of payments (*surséance van betaling*) being granted to the Company.

Page<sub>4</sub>

![A close-up of a logo AI-generated content may be incorrect.](ex5-1_001.jpg)

(C) A court applying the laws of the Netherlands may: (i) at the request of any party to an agreement change
the effect of an arrangement or dissolve it in whole or in part in the event of unforeseen circumstances (*onvoorziene omstandigheden*)
of such nature that do not, according the standards of reasonableness and fairness, justify the other party to expect the agreement to
be maintained unchanged; (ii) limit any claim for damages or penalties on the basis that such claim is deemed excessive by the court;
and (iii) refuse to give effect to any provisions for the payment of expenses in respect of the costs of enforcement (actual or attempted)
or unsuccessful litigation brought before such court or tribunal or where such court or tribunal has itself made an order for costs.

(D) The opinion expressed above may be limited or affected by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) claims based on tort (*onrechtmatige daad*);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) in relation to the issuance of the Registration Shares, including but not limited to an issuance below
market value, the rules of force majeure (*niet toerekenbare tekortkoming*), reasonableness and fairness (*redelijkheid en billijkheid*),
suspension (*opschorting*), dissolution (*ontbinding*), unforeseen circumstances (*onvoorziene omstandigheden*) and vitiated
consent (i.e., duress (*bedreiging*), fraud (*bedrog*), abuse of circumstances (*misbruik van omstandigheden*) and error
(*dwaling*)) or a difference of intention (*wil*) and declaration (*verklaring*).

(E) If a party is controlled by or otherwise connected with a person, organization or country that is currently
the subject of sanctions by the United Nations, the European Community or the Netherlands, implemented, effective or sanctioned in the
Netherlands under the Sanctions Act 1977 (*Sanctiewet 1977*), the Economic Offences Act (*Wet op de economische delicten*) or
the Financial Supervision Act (*Wet op het Financieel Toezicht*) or is otherwise the target of any such sanctions, the obligations
of the Company to that party may be unenforceable, void or otherwise affected.

(F) The term "non-assessable" has no equivalent legal term under Dutch law and for the purpose
of this opinion, "non-assessable" means that a holder of a Registration Share will not by reason of merely being such a holder,
be subject to assessment or calls by the Company or its creditors for further payment on such Registration Share.

This opinion is rendered to you for the sole purpose of the filing of this opinion as an exhibit to Form 8-K to be submitted by the Company on or around the date hereof, to which filing we consent under the express condition that:

(i) we do not admit that we are within the category of persons whose consent is required within Section 7
of the Securities Act of 1933;

(ii) any issues of interpretation or liability arising under this legal opinion will be governed exclusively
by the laws of the Netherlands and be brought exclusively before a Dutch court;

(i) this legal opinion is subject to acceptance of the limitation of liability as mentioned on the first page
of this letter. Subject to its terms, our insurance policy provides for a maximum insured amount of EUR 100,000,000;

(iii) we do not assume any obligation to notify or to inform you of any developments subsequent to the date
hereof that might render its contents untrue or inaccurate in whole or in part at such time; and

(iv) this legal opinion is strictly limited to the matters set forth herein and no opinion may be inferred
or implied beyond our opinion expressly stated herein.

Yours faithfully,

![](ex5-1_002.jpg)

CMS Derks Star Busmann N.V.

Page<sub>5</sub>